FDA Approves Preservative-Free Ketamine, Addressing Drug Shortage

NRx Pharmaceuticals has received FDA approval for its generic preservative-free ketamine injection, ahead of the agency's target date. This formulation, which does not contain benzethonium chloride, is intended to address drug shortages and is now available for supply to American hospitals and clinics. The approval by the FDA's Office of Generic Drugs demonstrates the agency's commitment to timely approval of drugs addressing shortages.